DOI:
10.1055/s-00050348
Indian Journal of Medical and Paediatric Oncology
LinksClose Window
References
Soverini S, De Benedittis C, Papayannidis C, Paolini S, Venturi C, Iacobucci I. et al.
Drug resistance and BCR-ABL kinase domain mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia from the imatinib to the second-generation tyrosine kinase inhibitor era: The main changes are in the type of mutations, but not in the frequency of mutation involvement.
Cancer 2014;
120: 1002-9
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.